.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,136,783

« Back to Dashboard

Claims for Patent: 6,136,783

Title: Antifungal compositions
Abstract:The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
Inventor(s): Neururkar; Maneesh J. (Lansdale, PA), Kaufman; Michael J. (New Hope, PA), Hunke; William A. (Harleysville, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/333,245
Patent Claims: 1. A method for treating an infection caused by Candida sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR9## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.

2. A method for treating an infection caused by Candida sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR10## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.

3. A method for treating an infection caused by Aspergillus sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR11## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer,

30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.

4. A method for treating an infection caused by Aspergillus sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR12## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.

5. A method for treating or preventing an infection or condition caused by Pneumocystis carinii in a patient in need of such treatment or prevention which comprises administering intravenously to said patient a preventative or therapeutic amount of a composition comprising 42 mg/ml of a compound having the formula ##STR13## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.

6. A method for treating or preventing an infection or condition caused by Pneumocystis carinii in a patient in need of such treatment or prevention which comprises administering intravenously to said patient a preventative or therapeutic amount of a composition comprising 42 mg/ml of a compound having the formula ##STR14## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc